St. Jude Medical (STJ) Reports In-Line Q3 EPS

St. Jude Medical (NYSE: STJ) reported Q3 EPS of $0.97, in-line with the analyst estimate of $0.97. Revenue for the quarter came in at $1.34 billion versus the consensus estimate of $1.35 billion.

St. Jude Medical sees Q4 2015 EPS of $1.00-$1.02, versus the consensus of $1.07.

St. Jude Medical sees FY2015 EPS of $3.93-$3.95, versus the consensus of $3.98.

For earnings history and earnings-related data on St. Jude Medical (STJ) click here.

You May Also Be Interested In

• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• ImmuCell reports 11.5% sales rise in Q2 2026, 20.9% gain for first half
• Levi (LEVI) Tops Q2 EPS by 4c, Offers Guidance